The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …

Since its approval in April 2018, osimertinib has been widely adopted as first-line therapy for
patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Understanding …

Lung cancer is the world's leading cause of cancer death and shows strong ancestry
disparities. By sequencing and assembling a large genomic and transcriptomic dataset of …

EGFR exon 20 insertion driver mutations (Exon20ins) in non–small cell lung cancer
(NSCLC) are insensitive to EGFR tyrosine kinase inhibitors (TKI). Amivantamab (JNJ …

Oncogenic KRAS is a major driver in lung adenocarcinoma (LUAD) that has yet to be
therapeutically conquered. Here we report that the SLC7A11/glutathione axis displays …

Lung cancer (LC), the leading cause of cancer-related deaths worldwide, is a complex and
highly heterogeneous disease. Additional to its biological complexity, LC patients are often …

Introduction Access to targeted therapies for lung cancer depends on the accurate
identification of patients' biomarkers through molecular testing. The International Association …

Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …

Lung cancer is the most often diagnosed cancer in the world and the most frequent cause of
cancer death. The prognosis for lung cancer is relatively poor and 75% of patients are …

Lung cancer is the leading cause of cancer death worldwide. In the past decade EGFR, ALK
and ROS1 TKIs lead to an unprecedented survival improvement of oncogene-addicted …